Regulus Therapeutics Announces Completion Of Enrollment In Second Cohort Of Phase 1b Multiple-Ascending Dose ) Clinical Trial of RGLS8429 For reatment Of Patients With Autosomal Dominant Polycystic Kidney Disease
Portfolio Pulse from Bill Haddad
Regulus Therapeutics has completed enrollment in the second cohort of its Phase 1b multiple-ascending dose clinical trial of RGLS8429 for the treatment of patients with Autosomal Dominant Polycystic Kidney Disease.
September 13, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regulus Therapeutics' completion of enrollment for its Phase 1b trial of RGLS8429 may accelerate the drug's development process.
The completion of enrollment for the Phase 1b trial of RGLS8429 indicates progress in the drug's development process. This could potentially lead to positive investor sentiment and a short-term increase in Regulus Therapeutics' stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100